Dr. Beth M. Leventhal, MD

Dr. Leventhal practices at South Florida Nephrology Consultants PL in Hollywood, Florida.

Dr. Leventhal's NPI, 1265468797, was assigned on June 25, 2006. Dr. Leventhal graduated from Albert Einstein College of Medicine in 1994. Dr. Leventhal holds Florida license ME0083467.

Dr. Leventhal's primary practice is South Florida Nephrology Consultants PL, at 1150 N 35th Ave, Hollywood, FL 33021 in Broward County. The practice phone is (954) 986-9008.

Dr. Leventhal's primary practice is South Florida Nephrology Consultants PL in Hollywood, Florida. Dr. Leventhal is also affiliated with Memorial Regional Hospital. The medical group on file is South Florida Nephrology Consultants. Dmand AI also links Dr. Leventhal to 4 more hospitals, 2 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leventhal practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Leventhal's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Leventhal is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Leventhal's licenses on file in 2 states: Florida and New York.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances, gout, kidney cysts, kidney disease and parathyroid gland disorder among the conditions Dr. Leventhal treats.

CMS data shows 985 Medicare services from Dr. Leventhal across 9 procedure codes in 2024, for 269 Medicare patients. Medicare paid $134,633 for them.

CMS counts 269 Medicare patients who saw Dr. Leventhal in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 4.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leventhal's median patient age at 71, with 51% women.

In 2024, Dr. Leventhal wrote 2,499 Medicare Part D claims for 494 patients. 83% of them were for generic drugs. CMS names the drug for 2,140 of them, across 53 drugs with 11 or more claims each, at $419,039 in total drug cost. In 2023, CMS named 1,685 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Leventhal for performance year 2024, reported individually. Dr. Leventhal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leventhal as offering telehealth.

CMS Open Payments shows 120 general payments to Dr. Leventhal from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. Calliditas Therapeutics US Inc. paid the most, $2,159.

Dmand AI lists 3 awards for Dr. Leventhal, most recently CMS Stage 1 EHR in 2013.

Dr. Leventhal graduated from Albert Einstein College of Medicine in 1994.

Dr. Leventhal is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.